Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA.
Am J Hum Genet. 2020 May 7;106(5):707-716. doi: 10.1016/j.ajhg.2020.04.002.
Because polygenic risk scores (PRSs) for coronary heart disease (CHD) are derived from mainly European ancestry (EA) cohorts, their validity in African ancestry (AA) and Hispanic ethnicity (HE) individuals is unclear. We investigated associations of "restricted" and genome-wide PRSs with CHD in three major racial and ethnic groups in the U.S. The eMERGE cohort (mean age 48 ± 14 years, 58% female) included 45,645 EA, 7,597 AA, and 2,493 HE individuals. We assessed two restricted PRSs (PRS and PRS; 28 and 50 variants, respectively) and two genome-wide PRSs (PRS and PRS; 1.7 M and 6.6 M variants, respectively) derived from EA cohorts. Over a median follow-up of 11.1 years, 2,652 incident CHD events occurred. Hazard and odds ratios for the association of PRSs with CHD were similar in EA and HE cohorts but lower in AA cohorts. Genome-wide PRSs were more strongly associated with CHD than restricted PRSs were. PRS, the best performing PRS, was associated with CHD in all three cohorts; hazard ratios (95% CI) per 1 SD increase were 1.53 (1.46-1.60), 1.53 (1.23-1.90), and 1.27 (1.13-1.43) for incident CHD in EA, HE, and AA individuals, respectively. The hazard ratios were comparable in the EA and HE cohorts (p = 0.77) but were significantly attenuated in AA individuals (p= 2.9 × 10). These results highlight the potential clinical utility of PRSs for CHD as well as the need to assemble diverse cohorts to generate ancestry- and ethnicity PRSs.
由于冠心病 (CHD) 的多基因风险评分 (PRSs) 主要来自欧洲血统 (EA) 队列,因此其在非洲血统 (AA) 和西班牙裔 (HE) 个体中的有效性尚不清楚。我们在美国三个主要种族和族裔群体中研究了“受限”和全基因组 PRSs 与 CHD 的关联。eMERGE 队列(平均年龄 48 ± 14 岁,女性占 58%)包括 45645 名 EA、7597 名 AA 和 2493 名 HE 个体。我们评估了来自 EA 队列的两个受限 PRSs(PRS 和 PRS;分别有 28 和 50 个变体)和两个全基因组 PRSs(PRS 和 PRS;分别有 170 万和 660 万个变体)。在中位随访 11.1 年后,发生了 2652 例 CHD 事件。在 EA 和 HE 队列中,PRSs 与 CHD 相关的风险和优势比相似,但在 AA 队列中较低。全基因组 PRSs 与 CHD 的相关性强于受限 PRSs。在所有三个队列中,表现最佳的 PRS PRS 均与 CHD 相关;每增加 1 个 SD,CHD 的风险比(95%CI)分别为 1.53(1.46-1.60)、1.53(1.23-1.90)和 1.27(1.13-1.43)。EA、HE 和 AA 个体的 CHD 发生率分别为 1.53(1.46-1.60)、1.53(1.23-1.90)和 1.27(1.13-1.43)。EA 和 HE 队列中的风险比相当(p=0.77),但在 AA 个体中显著减弱(p=2.9×10)。这些结果突出了 PRSs 对 CHD 的潜在临床应用价值,以及需要组建多样化的队列来生成与血统和种族相关的 PRSs。